Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FH6P
|
|||
| Drug Name |
PMID28454500-Compound-34
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA UNIVERSIDAD AUTONOMA DE MADRID DNS NEUROSCIENCE
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H22N2O3
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)C=CC(=O)OC2=CC3=C(C=C2)NC=C3CCNC(=O)C
|
|||
| InChI |
1S/C22H22N2O3/c1-15-3-5-17(6-4-15)7-10-22(26)27-19-8-9-21-20(13-19)18(14-24-21)11-12-23-16(2)25/h3-10,13-14,24H,11-12H2,1-2H3,(H,23,25)/b10-7+
|
|||
| InChIKey |
FKXPVWWTKVQISE-JXMROGBWSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cysteines of Keap1 (KEAP1 Cysteines) | Target Info | Modulator | [1] |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [1] | |
| Target's Patent Info | Cysteines of Keap1 (KEAP1 Cysteines) | Target's Patent Info | [1] | |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.